DOJ launches investigation into McKinsey’s past work for opioid manufacturers; Spending on GLP-1 drugs balloons; UnitedHealth Group is shutting down Optum’s virtual care business.
Biogen beats analyst estimates with Leqembi boost, Roche sales fall in Q1
In addition to Leqembi, Biogen’s postpartum depression drug Zurzuvae generated $12 million in quarterly revenues, topping the $2 million it brought in last quarter.
Five things for pharma marketers to know for Wednesday morning
The Supreme Court is slated to hear a case about the Emergency Medical Treatment and Labor Act; Xaira Therapeutics launches with the goal of using AI to transform drug R&D; Flonase forges a Bridgerton connection for its ‘Polin’ ad campaign.
Novartis raises guidance following strong Q1 earnings
Some of the top growth drivers for Novartis included Entresto, which generated $1.8 billion in sales as well as Cosentyx, which generated $1.3 billion.
Big Pharma market caps surge to start 2024 despite economic headwinds
The top 20 drugmakers — led by GLP-1 manufacturers Eli Lilly and Novo Nordisk — reported a total increase of 9.6% in market capitalization in the first quarter of 2024.
Five things for pharma marketers to know for Tuesday morning
Cardinal Health loses a major contract with OptumRx; The Supreme Court declines to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz; Ogilvy-backed campaign asks if men have the balls to take a pregnancy test for testicular cancer.